Table II.
Agglutination activity of Gleheda towards normal and polyagglutinable human erythrocytes
| Cells
|
Agglutination Activity
|
Significant Structures Associated with Blood Group
|
|
|---|---|---|---|
| MCAa | RAb | ||
| μg mL-1 | |||
| O | 5.3 | 1 | Fuc α(1,2) Gal β(1,4) GlcNAc β(1,3) Gal-R |
| O papain treated | >168 | <0.03 | Fuc α(1,2) Gal β(1,4) GlcNAc β(1,3) Gal-R |
| A1 | 5.3 | 1 | GalNAc α(1,3) [Fuc α(1,2)] Gal β(1,4) GlcNAc β(1,3) Gal-R |
| GalNAc α(1,3) [Fuc α(1,2)] Gal β(1,3) GalNAc α(1,3) [Fuc α(1,2)]Gal-β(1,4) GlcNAc-R | |||
| A2 | 5.3 | 1 | GalNAc α(1,3) [Fuc α(1,2)] Gal β(1,4) GlcNAc β(1,3) Gal-R |
| B | 10.6 | 0.5 | Gal α(1,3) [Fuc α(1,2)] Gal β(1,4) GlcNAc β(1,3) Gal-R |
| Tn (n = 4) | 0.01-0.16 | 32-512 | GalNAc α-Ser/Thr |
| Tn papain treated | 2.6 | 2 | Greatly reduced amounts of GalNAc α-Ser/Thr |
| Cad (n = 3) | 0.16-10.6 | 0.5-32 | Neu5Ac α(2,3) [GalNAc β(1,4)] Gal β(1,3) [Neu5Ac α(2,6)]GalNAc α-Ser/Thr |
| Cad neuraminidase (n = 2) | 0.66-1.3 | 4-8 | GalNAc β(1,4) Gal β(1,3) GalNAc α-Ser/Thr |
| Sd(a++) (n = 7) | 10.6-168 | 0.03-0.5 | Neu5Ac α(2,3) [GalNAc β(1,4)]Gal β(1,4) GlcNAc β(1,3)Gal |
| T | 0.16 | 32 | Gal β(1,3) GalNAc α-Ser/Thr |
| T papain treated | >168 | <0.03 | Greatly reduced amounts of Gal β(1,3) GalNAc α-Ser/Thr |
| T + Tk | 2.6 | 2 | Gal β(1,3) GalNAc α-Ser/Thr & GlcNAc β(1,3) Gal-R |
| Tk (O, enzyme modified) | > 168 | <0.03 | GlcNAc β(1,3) Gal-R |
| Th | 1.3 | 4 | Neu5Ac α(2,3) Gal β(1,3) [Neu5Ac α(2,6)]GalNAc α-Ser/Thr (Partially reduced sialic acid) |
| Acquired B (n = 2) | 5.3-42.4 | 0.12-1 | GalN α(1,3) [Fuc α(1,2)] Gal β(1,4) GlcNAc β(1,3) Gal-R |
a
Minimal concentration required for agglutination. b Relative agglutinability” of cells (compared with that of type O cells).